Neumora Therapeutics, Inc. (NMRA)Healthcare | Biotechnology | Watertown, United States | NasdaqGS
2.15 USD
+0.15
(7.500%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.09 -0.06 (-0.060%) ⇩ (April 17, 2026, 7:40 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:21 p.m. EDT
NMRA is a highly volatile stock with a strong beta of 3.12, indicating it is more sensitive to market movements. The recent price history shows a significant dip, with the stock trading near its 52-week low. Despite some analyst buy ratings and positive news, the company's fundamentals are weak, with negative earnings and a high debt-to-equity ratio. The lack of dividends and the negative forward PE suggest that the stock is not a safe investment for long-term growth. Short-term traders may look for a rebound, but the forecasting model's low accuracy and mixed options activity suggest caution. Investors should consider the high risk and limited upside potential before entering this stock. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.228502 |
| AutoETS | 0.228503 |
| MSTL | 0.240080 |
| AutoTheta | 0.300323 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.06 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.090 |
| Excess Kurtosis | -1.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 52.959 |
| Market Cap | 391,388,032 |
| Forward P/E | -2.33 |
| Beta | 3.12 |
| Website | https://www.neumoratx.com |
As of April 11, 2026, 4:21 p.m. EDT: Options speculators are showing mixed signals. The calls and puts data indicate a cautious outlook with elevated implied volatility (IV) on certain strikes, particularly for out-of-the-money (OTM) calls and puts. The presence of significant open interest (OI) on OTM calls and puts suggests uncertainty about future price direction. While some traders are positioning for potential upside (OTM calls with high OI), others are hedging against downside risk (OTM puts with high OI). The ATM strikes are showing lower IV, which could indicate a lack of consensus on the immediate price movement. Overall, the options activity suggests a wait-and-see attitude, with traders anticipating potential volatility.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.2575758 |
| Address1 | 490 Arsenal Way |
| Address2 | Suite 200 |
| All Time High | 21.0 |
| All Time Low | 0.611 |
| Ask | 2.19 |
| Ask Size | 12 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 1,213,430 |
| Average Daily Volume3 Month | 1,262,775 |
| Average Volume | 1,262,775 |
| Average Volume10Days | 1,213,430 |
| Beta | 3.12 |
| Bid | 2.13 |
| Bid Size | 12 |
| Book Value | 0.596 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.15 |
| Current Ratio | 5.872 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.19 |
| Day Low | 1.99 |
| Debt To Equity | 52.959 |
| Display Name | Neumora Therapeutics |
| Earnings Call Timestamp End | 1,774,872,000 |
| Earnings Call Timestamp Start | 1,774,872,000 |
| Earnings Timestamp | 1,774,873,800 |
| Earnings Timestamp End | 1,778,070,600 |
| Earnings Timestamp Start | 1,778,070,600 |
| Ebitda | -235,948,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.118 |
| Enterprise Value | 263,867,024 |
| Eps Current Year | -0.98822 |
| Eps Forward | -0.92423 |
| Eps Trailing Twelve Months | -1.45 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.7223 |
| Fifty Day Average Change | -0.57229996 |
| Fifty Day Average Change Percent | -0.21022663 |
| Fifty Two Week Change Percent | 225.75757 |
| Fifty Two Week High | 3.65 |
| Fifty Two Week High Change | -1.5 |
| Fifty Two Week High Change Percent | -0.4109589 |
| Fifty Two Week Low | 0.611 |
| Fifty Two Week Low Change | 1.539 |
| Fifty Two Week Low Change Percent | 2.5188217 |
| Fifty Two Week Range | 0.611 - 3.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,694,698,200,000 |
| Float Shares | 104,557,037 |
| Forward Eps | -0.92423 |
| Forward P E | -2.326261 |
| Free Cashflow | -115,712,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 96 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.24249001 |
| Held Percent Institutions | 0.56207 |
| Implied Shares Outstanding | 182,040,945 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-09-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. |
| Long Name | Neumora Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 391,388,032 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1684602478 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -236,928,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 391,388,031 |
| Number Of Analyst Opinions | 8 |
| Open | 2.04 |
| Operating Cashflow | -206,440,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 857 760 0900 |
| Post Market Change | -0.06000018 |
| Post Market Change Percent | -2.790706 |
| Post Market Price | 2.09 |
| Post Market Time | 1,776,469,204 |
| Previous Close | 2.0 |
| Price Eps Current Year | -2.1756291 |
| Price Hint | 4 |
| Price To Book | 3.6073825 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.625 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.77778 |
| Region | US |
| Regular Market Change | 0.15 |
| Regular Market Change Percent | 7.5 |
| Regular Market Day High | 2.19 |
| Regular Market Day Low | 1.99 |
| Regular Market Day Range | 1.99 - 2.19 |
| Regular Market Open | 2.04 |
| Regular Market Previous Close | 2.0 |
| Regular Market Price | 2.15 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,419,514 |
| Return On Assets | -0.58107 |
| Return On Equity | -1.21211 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 182,040,945 |
| Shares Percent Shares Out | 0.0238 |
| Shares Short | 4,326,409 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 5,216,610 |
| Short Name | Neumora Therapeutics, Inc. |
| Short Percent Of Float | 0.054899998 |
| Short Ratio | 4.09 |
| Source Interval | 15 |
| State | MA |
| Symbol | NMRA |
| Target High Price | 18.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 8.9075 |
| Target Median Price | 7.63 |
| Total Cash | 182,530,000 |
| Total Cash Per Share | 1.003 |
| Total Debt | 55,009,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.45 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.128905 |
| Two Hundred Day Average Change | 0.021095037 |
| Two Hundred Day Average Change Percent | 0.009908867 |
| Type Disp | Equity |
| Volume | 1,419,514 |
| Website | https://www.neumoratx.com |
| Zip | 2,472 |